This study is currently not recruiting participants.

A Phase 2 Open-Label Single-Arm Study of Brentuximab Vedotin in Patients with CD30-Positive Nonlymphomatous Malignancies

Study of a Treatment for CD30 Antigen Cancer

Not Recruiting
6 years - 100 years
All
Phase N/A
1 Location

Brief description of study.

This study is being done to test whether brentuximab vedotin has an effect on cancer that is characterized by the CD30 antigen.

Detailed description of study

This study is being done to test whether brentuximab vedotin has an effect on cancer that is characterized by the CD30 antigen.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: CD30-Positive Nonlymphomatous Malignancies
  • Age: 6 years - 100 years
  • Gender: All

This study investigates the effects of an investigational medication on cancer characterized by the CD30 antigen. The CD30 antigen is a protein found on the surface of some cancer cells, which can be targeted by specific treatments.

Participants in this study will receive the investigational medication to assess its impact on their cancer. The study aims to understand how the medication interacts with the CD30 antigen and its potential effects on cancer cells.

  • Who can participate: Participants should be adults diagnosed with CD30 antigen-positive cancer. Additional eligibility criteria may apply based on health status and previous treatments.
  • Study details: Participants will receive the investigational medication to evaluate its effects on CD30 antigen cancer.
Updated on 19 Feb 2024. Study ID: 1111007468

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team